title: [Clinical study of long-term docetaxel based chemotherapy treatment for patients with castration-resistant prostate cancer].
abstract: OBJECTIVE
  To evaluate long-term continuous administration of docetaxel (DOC), over survival rate, PSA level and adverse effects were analyzed, retrospectively. We also compared the results of long-term treatment group and short-term treatment group.
  
  
  METHODS
  This study reported that 14 cases of long-term continuous administration of DOC consisting of 11 or more cycles among 51 patients of castration-resistant prostate cancer (CRPC) treated with DOC from October 2008 to September 2013 at our institution, retrospectively. Nineteen patients who had treated with DOC 10 or less cycles were defined as short-term dose group, and both groups were compared. DOC was administered every 3 to 4 weeks at 60 to 70 mg/m2, and was treated with prednisolone at 10 mg/day as a general.
  
  
  RESULTS
  The median number of treatment cycles was 15. Thirteen cases showed a decrease in PSA levels and 10 cases showed a decrease in PSA levels of 50% or more, the 1-year survival rate of long-term dose and short-term dose group were 100% and 16%. Adverse effects of grade 3 or lower consisted of leukocytopenia in 85% and thrombocytopenia in 28%, however, grade 4 or higher were not observed in long-term dose group. In multivariable analysis of parameters, long-term treatment was related to PSA levels at start of treatment and ALP levels.
  
  
  CONCLUSIONS
  Forty-two percent of patients who have CRPC at our institution undergo long-term DOC based chemotherapy treatment It may be suggested that long-term DOC based chemotherapy for some cases contribute to extend survival time with no serious adverse events.
authors.forename: Koichi
authors.initials: K
authors.lastname: Miyamae
authors.forename: Kosuke
authors.initials: K
authors.lastname: Kitani
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Hara
authors.forename: Kensuke
authors.initials: K
authors.lastname: Nakakuma
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Hamada
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Yamasaki
authors.forename: Miyo
authors.initials: M
authors.lastname: Horio
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Miyamura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel